Using Gelatin Nanoparticle Mediated Intranasal Delivery of Neuropeptide Substance P to Enhance Neuro-Recovery in Hemiparkinsonian Rats

Ying-Zheng Zhao\(^1,2,3\), Rong-Rong Jin\(^1\), Wei Yang\(^1\), Qi Xiang\(^5\), Wen-Ze Yu\(^1\), Qian Lin\(^1\), Fu-Rong Tian\(^1\), Kai-Li Mao\(^1\), Chuan-Zhu Lv\(^3\), Yi-Xiang J. Wang\(^6\)*, Cui-Tao Lu\(^2,1\)*

\(^1\) College of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China, \(^2\) The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China, \(^3\) Hainan Medical College, Haikou, Hainan 570102, China, \(^4\) Taizhou Traditional Chinese Medical Hospital, Taizhou, Zhejiang 318000, China, \(^5\) Biopharmaceutical R&D Center of Jinan University, Guangzhou, Guangdong 510000, China, \(^6\) Department of Imaging and Interventional Radiology, Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SA

\* These authors contributed equally to this work.

\* yixiang_wang@cuhk.edu.hk (YXW); lctuua@sina.com (CTL)

Abstract

Purpose

Intranasal administration of phospholipid-based gelatin nanoparticles (GNP) was prepared to investigate the neuro-recovery effects of neuropeptide Substance P (SP) on hemiparkinsonian rats.

Methods

The SP-loaded gelatin nanoparticles (SP-GNP) were prepared by a water-in-water emulsion method and possessed high stability, encapsulating efficiency and loading capacity. PC-12 cells were used to examine the growth enhancement of SP-GNP in vitro by MTT assays and flow cytometry (FCM). The therapeutic effects of SP-GNP on 6-hydroxydopamine (6-OHDA) induced hemiparkinsonian rats were assessed by quantifying rotational behavior and the levels of tyrosine hydroxylase (TH), phosphorylated c-Jun protein (p-c-Jun) and Caspase-3 (Cas-3) expressed in substantia nigra (SN) region of hemiparkinsonian rats.

Results

PC-12 cells under SP-GNP treatment showed better cell viability and lower degree of apoptosis than those under SP solution treatment. Hemiparkinsonian rats under intranasal SP-GNP administration demonstrated better behavioral improvement, higher level of TH in SN along with much lower extent of p-c-Jun and Cas-3 than those under intranasal SP solution administration and intravenous SP-GNP administration.
Conclusions

With the advantages of GNP and nose-to-brain pathway, SP can be effectively delivered into the damaged SN region and exhibit its neuro-recovery function through the inhibition on JNK pathway and dopaminergic neuron apoptosis.

Introduction

Parkinson’s disease (PD) is a chronic disorder of the central nervous system (CNS). PD is caused primarily by progressive loss of dopaminergic cells in the substantia nigra (SN) region, which leads to bradykinesia, muscular rigidity, resting tremor, and postural instability[1, 2]. PD affects 1%-2% of the population above the age of 60 [3]. Despite the progress for therapy of Parkinson’s disease, it remains a difficult disease for clinical management.

Neuropeptide Substance P (SP) is a member of the tachykinin peptide family that is involved in the regulation of many biological processes. SP is a major mediator of neuroimmunomodulatory activities and neurogenic inflammation within the central and peripheral nervous system [4]. SP-containing neurons are widely distributed throughout the central and peripheral nervous systems, especially in the SN region [5]. From in vitro experiments, SP can protect dopamine (DA) neurons from neurotoxicity, decrease neuron apoptosis and enhance cell growth [6]. From in vivo studies, the expression of SP as well as DA is significantly reduced in the substantia nigra (SNc) of hemiparkinsonian rats and PD patients, which results in increased DA deaths and limited expression of tyrosine hydroxylase (TH) [7]. Researchs have also shown that SP plays an important regulatory role on dopaminergic pathways, particularly the nigrostriatal pathway [8]. After SP or SP receptor antagonist treatment for the rat model of Parkinson’s disease, the content of striatal dopamine and its metabolites increase, and PD symptoms improve [9, 10]. In rats with substantia nigra partially damaged by 6-OHDA, systemic administration of SP before and after the damage promotes functional recovery of Parkinson’s disease [10, 11].

Abnormally activated c-Jun N-terminalkinase (JNK) pathway is one of the important mechanisms leading to DA neuronal apoptosis in SN region [12]. JNK is one of the important members of mitogen-activated protein kinase, MAPK family. It has an important regulatory role for a variety of cells including nerve cells for their growth, differentiation, survival, and apoptosis [13]. Studies have shown that abnormal activation of JNK signaling pathway can activate downstream signaling pathways, leading to the death of DA neurons. Thus JNK signaling pathway plays an important role in the dopaminergic neuron apoptosis in Parkinson’s disease [14]. By inhibiting the abnormal activation of JNK pathway, SP can execute certain therapeutic effects for Parkinson’s disease [15, 16].

Dopaminergic neuron apoptosis is also one of major causes of Parkinson’s disease [17]. The apoptotic process mainly results from protease cascade process mediated by Caspase family member. Caspase-3 has a vital role in the reaction process. From previous studies, 6-OHDA can induce apoptosis in PC12 cells by activating caspase and pro-apoptotic factor as well as transduction of Bax factor [18]. 6-OHDA injection into the rat brain can be used to induce the apoptosis of DA neurons in substantia nigra [19]. Researchs have also found that SP can effectively regulate the expression of caspase family proteins and cell apoptosis, thereby inhibit the symptoms of many diseases including cancer [20], spinal cord injury [21] and Parkinson’s disease [16]. Meanwhile, JNK signaling pathway downstream mitochondrial malfunction can lead to over-expression of Caspase-3 protein, ultimately leading to apoptosis or degenerative death of cells [13].
SP can play an important role in the recovery of diseased dopaminergic neuron through the deactivation of JNK pathway and decreasing neuron apoptosis. However, as a macromolecule neurokinin, it is not likely that SP administrated orally or intravenously could cross the blood-brain barrier (BBB) and its role in the treatment of brain diseases is therefore significantly restrained.

Intranasal delivery of biologics has been proved as a noninvasive and efficient strategy [22]. From previous studies, drugs or particles with a size below 300 nm could bypass BBB and play therapeutic roles at certain regions inside the brain [23, 24]. With intranasal pathway, these drugs or particles can be absorbed through mucous membrane inside nasal olfactory region, and then delivered into the brain directly through the cribriform plate. However, what cannot be overlooked is the short resident time of biologics in the nasal cavity for absorption, which decreases the concentration of drug in brain and compromises the therapeutic effect for diseases like Parkinson’s disease [25, 26]. With the development of nanomedicine, nanoparticles have emerged as a promising approach for delivering therapeutic agent across the BBB [27–30]. Lipid nanoparticles with solid matrix possess some advantages over other colloidal systems such as liposomes, emulsion, micro/nanoparticles, which include possibility of controlled release, drug targeting, increased stability, high payload, incorporation of both hydrophilic and hydrophobic drugs, and low biotoxicity [31, 32]. The gelatin nanoparticle used in this study is a type of gelatin-cored nanostructured lipid carrier with high stability, strong penetration, encapsulating efficiency, loading capacity as well as bioactivity [33]. It is reported that gelatin nanoparticles are excellent carriers for targeted delivery, making it possible to delivery therapeutics to special tissue effectively without compromising drug stability and concentration [34, 35].

The current study investigated whether SP-GNP can be delivered into CNS to play a neuroprotective role on hemiparkinsonian rats by inhibiting activation of JNK pathway and decrease dopaminergic neuron apoptosis. In this study, physicochemical properties of the prepared gelatin nanoparticles, including micromorphology, particle size, Zeta potential, encapsulating efficiency and loading capacity, were characterized. The growth promoting effect of SP solution and SP-GNP on 6-OHDA diseased PC-12 cells were assessed by MTT assays and flow cytometry analysis. The neuroprotective effect and the inhibition of JNK pathway activation and dopaminergic neuron apoptosis by intranasally administrated SP-GNP on hemiparkinsonian rats were evaluated by behavioral assessment, immunohistochemical staining and Western Blot analysis.

Materials and Methods

Materials and animals

Consent and approval for this investigation were obtained from the Laboratory Animal Ethics Committee of Wenzhou Medical University & Laboratory Animal Centre of Wenzhou Medical University (Wenzhou, Zhejiang, China). Rats were provided by the Laboratory Animal Centre of Wenzhou Medical University. Male SD rats weighed around 300~320g were used in the study. Two to three animals were housed per stainless steel cage on a 12-h light/12-h dark cycle in an air-conditioned room at 22°C, and check daily by the animal care staff. A standard commercial rat chow and water were available ad libitum.

Preparation and characterization of SP-GNP and blank GNP

All reagents used in this study were commercially available. SP was purchased from GL Biochem (Shanghai) Ltd. Its molecular structure is shown in Fig 1 and its moleculer weight was 1347. The SP-GNP and blank GNP were prepared using water-in-water emulsion and freeze-
drying technique [36, 37]. Briefly, high concentration SP was dissolved in 1 ml of 20% w/v Poloxamer 188-grafted heparin copolymer solution. The solution was added into 2 ml of 2.0% w/v gelatin solution to produce a homogeneous mixture. Under sonication (110 w, 15°C) using a probe sonicator, D, L-glyceraldehyde was injected into the mixture until its final concentration reached 0.1% w/v to initiate the cross-linking reaction. The mixture solution was bathed at 5°C under magnetic stirring at 2500 rpm for 5 h to form the SP gelatin nanoparticles suspension. The suspension was lyophilized to gain SP gelatin polymeric nanoparticles (SP-GNs) powder. Then lyophilized SP-GNs powder was dispersed in solution containing HSPC, trehalose and cholesterol. By sonication (90 w, 20 s) at 25°C, the mixture suspension was then lyophilized to gain lyophilized powder containing SP-GNP, which was reconstituted in double-distilled water to form SP-GNP suspension for administration.

Blank GNP (using gelatin solution instead of SP gelatin solution in preparation) and SP solution (SP dissolved in 0.9% NaCl solution) were also prepared for the following experiments. The final SP concentration in SP-containing solution was 2 mg/mL.

The morphologies of loaded or unloaded gelatin polymeric nanoparticles and gelatin nanoparticles were determined using a scanning electron microscopy (SEM) (X-650, Hitachi Co. Ltd., Tokyo, Japan). Their size and zeta potential values were determined by dynamic light scattering using a Zeta Potential/Particle Sizer Nicomp™ 380 ZLS (PSS. Nicomp, Santa Barbara, CA, USA).

To determine the encapsulating efficiency of SP-GNs and SP-GNP, approximately 1.5 mL of the SP-GNs or SP-GNP dispersion was placed in microtubes and was centrifuged at 10,000 g for 40 min. The supernatant was then collected and diluted for content determination of SP using an ELISA kit. The drug encapsulation efficiency was calculated as indicated below. The analyses were performed in triplicate.

Encapsulation efficiency (%) = (total amount of drug − amount of drug in supernatant) / total amount of drugs added initially × 100%

Experiments in vitro

Cell culture. Male rat adrenal pheochromocytoma PC-12 cell was used for the in vitro studies. PC-12 cell was cultured in DMEM high-glucose medium with 10% FBS and 1% penicillin as well as streptomycin in humidified incubator (Thermo) containing 5% CO2 at 37°C. The cells in their logarithmic growth phase were harvested with trypsin for further experiments.
The growth enhancement of SP on 6-OHDA diseased PC-12 cells was confirmed by MTT assay. First of all, the suitable concentration of 6-OHDA to induce the disease model was determined. All cells were cultured in 96 well plates for 24 hours with a density of 5000 cells per well. With blank PC-12 cells as the control, four levels of 6-OHDA concentrations (25, 50, 75, 100 μmol/L) were incubated with PC-12 cells for 24 hours before 10μL of 5mg/mL of MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide] was added into each well and incubated for 4 hours. Then 100 μL of Formanzan solution was added into each well and incubated for another 4 hours to dissolve the crystals occurred in each well. Next, the plate was put in a microplate reader to measure the optical density at 526 nm and quantify the extent of cell viability. The lower extent of cell viability, the more damage 6-OHDA was done to the cells. The concentration causing the lowest extent of cell viability was chosen to set up the diseased cell model in the following assays.

Next was to choose the suitable SP concentration that could enhance cell growth. All cells were cultured in 96 well plates for 24 hours with a density of 5000 cells per well. With blank PC-12 cells as the control, six levels of SP concentrations (0, 1, 10, 100, 1000, 10000 nmol/L) were incubated with PC-12 cells for 24 hours before 10μL of 5mg/mL of MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide] was added into each well and incubated for 4 hours. Then 100 μL of Formanzan solution was added into each well and incubated for another 4 hours, dissolving the crystals occurred in each well. Next, the plate was put in a microplate reader to measure the optical density at 526 nm and quantify the extent of cell viability. The higher extent of cell viability, the better effect SP was on cells. The concentrations raised the extent of cell viability were proved to enhance cell growth and were used in the following assays.

The final step was to investigate if SP solution and SP-GNP could enhance growth on diseased cells. All cells were cultured in 96 well plates for 24 hours with a density of 5000 cells per well. With blank PC-12 cells as the control, 6-OHDA in the most suitable concentration was used on cells for 24 hours to induce the diseased cell model. Then, different concentrations of SP solution and SP-GNP were incubated with PC-12 cells for 24 hours before 10μL of 5mg/mL of MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide] was added into each well and incubated for 4 hours. Then 100 μL of Formanzan solution was added into each well and incubated for another 4 hours, dissolving the crystals occurred in each well. Next, the plate was put in a microplate reader to measure the optical density at 526 nm and quantify the extent of cell viability. The higher extent of cell viability, the better effect SP solution or SP-GNP was on cells.

Flow cytometry. All cells were cultured in 12 well plates for 24 hours with a density of 50000 cells per well. With blank PC-12 cells as the control, 6-OHDA was added to cells for 24 hours to induce the diseased cell model. Different concentrations of SP solution and SP-GNP were then incubated with PC-12 cells for 24 hours before the cells were resuspended with 195μL binding buffer. Next, 5 μL of Annexin V-FITC was added and incubated for 10 minutes at room temperature in the dark. Then, the cells were resuspended with 190μL binding buffer again into tubes and 10 μL of Propidium Iodide (PI) was added. Finally, the tubes were placed in ice and the extent of cell apoptosis was detected in the Annexin V-FITC and PI channels of the flow cytometer. Apoptotic cells were stained red with Annexin V-FITC, and necrotic cells were stained green with PI, while normal cells were not stained. Lower extent of cell apoptosis suggests better enhancement of SP solution or SP-GNP on cells.
Experiments in vivo

Hemiparkinsonian rat model. As seen in Fig 2, SD rats were anesthetized with pentobarbital sodium (60 mg/kg) and then injected with 12 μL 6-OHDA solution in the right-side striatum (or vehicle for sham animals) by use of the stereotaxic apparatus [38, 39]. Gentamicin was given after those procedures to prevent possible infection.

Four weeks after 6-OHDA solution injection, the behavior evaluation of apomorphine-induced rotations was conducted to determine if the hemiparkinsonian rat model was successfully set up. The rats were injected with apomorphine (0.5 mg/kg) subcutaneously, and then both contra- and ipsi-lateral full-body rotations in the following 30 minutes were recorded. The rats had over 7 full-body contralateral rotations per minute were considered as successful hemiparkinsonian model rats (PD rats), which were used in the following experiments.

Treatment of hemiparkinsonian rats. After the behavior evaluation, sham SD rats and PD rats were divided into six groups randomly (n = 6/group) and started daily treatment for two weeks. As seen in Table 1, group 1 was sham rats with intranasal PBS treatment. Group 2–4 were PD rats which received intranasal PBS, blank GNP and SP solution respectively. Group 5 and group 6 were PD rats received SP-GNP intranasally and intravenously.

### Table 1. Groups designed for two-week daily treatment (n = 6/group).

| Group | Rats                  | Administration |
|-------|-----------------------|----------------|
| 1     | Sham                  | in.PBS         |
| 2     | Hemiparkinsonian      | in.PBS         |
| 3     | Hemiparkinsonian      | in.Blank GNP   |
| 4     | Hemiparkinsonian      | in.SP solution |
| 5     | Hemiparkinsonian      | iv.SP-GNP      |
| 6     | Hemiparkinsonian      | in.SP-GNP      |

Note: in. represents intranasal administration; iv. represents intravenous administration.

doi:10.1371/journal.pone.0148848.t001
After the two-week daily treatment, the experimental rats were injected subcutaneously with apomorphine (0.5 mg/kg) to evaluate their neuro-recovery extent. During the 30 minutes after apomorphine injection, rats’ all contra- and ipsi-lateral full-body rotations were measured. The rat groups with low rotations suggested some neuro-recovery.

The rats were then all sacrificed and their brains were collected for coronal sectioning across the striatum region as well as the SNc region. Half of them were embedded in paraffin and sectioned for histopathological study and immunohistochemical staining, while the rest were dissected and homogenized in cold lysis buffer for Western blot assessment.

**Histopathological study.** The paraffin sections were handled with conventional deparaffinization and hydration steps before incubating in hematoxylin for 7 min. Next, the sections were washed with cold running water for 9 min and soaked in 95% ethanol for 5 sec, and incubated in eosin for 30 sec. Then a drop of permount and a glass slip were added to the sections. Finally, the sections were placed under optical microscope to study the microstructure.

**Immunohistochemical staining.** The immunohistochemical staining with anti-TH antibody, anti-p-c-Jun antibody and anti-Caspase-3 antibody was conducted to evaluate therapeutic effect of different SP preparations on hemiparkinsonian rats.

Tyrosine hydroxylase (TH) is the rate-limiting enzyme to catalyze the hydroxylation of L-tyrosine to L-3,4-dihydroxyphenylalanine (L-DOPA), the precursor to dopamine, norepinephrine and epinephrine. TH is considered a marker for dopaminergic neurons [40]. Higher ratio of TH staining suggests less loss of dopaminergic neurons. Phosphorylated c-Jun protein (p-c-Jun) is a vital protein in JNK pathway. As the primary endpoint shear enzyme in the process of cell apoptosis, Caspase-3 plays an irreplaceable part during cell apoptosis. The ratio of p-c-Jun and Caspase-3 staining suggests their levels in SN regions.

**Western blot assessment.** Western blot assessment was carried out to evaluate the TH, p-c-Jun and Caspase-3 levels in SN area of experimental rats. Proteins were extracted in an ice bath and their levels were assessed using standard biochemical procedures [4]. The band densities were quantified by densitometry (Quantity One software, Bio-Rad, Hercules, CA, USA).

**Statistical analysis**

Statistically significant difference for multiple groups was determined using a one way ANOVA with a Newman-Keuls post-hoc test. Statistical significance between individual groups was determined using a Mann-Whitney U test. All testing was done with Statistical Program for Social Sciences (Spass) 19. Difference was considered statistically significant when the p-value was less than 0.05.

**Results**

**Physicochemical properties and bioactivity of gelatin nanoparticle**

From SEM micrographs, the blank GNP and SP-GNP were uniform in shape and size (Fig 3). Characterizations of GNs and GNPs loaded with or without SP were shown in Table 2. The dynamic light scattering results demonstrated that the average particle size of blank GNs and GNPs were 87±1.01 nm and 136±1.32 nm respectively. The polydispersibility index (PDI) represents the distribution of particle size. Low PDI values were observed for both of blank GNP and SP-GNP (Table 2), indicating blank GNP and SP-GNP approached a monodisperse stable system. After SP loading, the mean diameters of nanoparticle increased, not exceeding 200 nm (Table 2). The zeta potential is an important index evaluating the physical stability of nanoparticles. Nanoparticles with high absolute value of zeta potential are electrically stable while those with low absolute value of zeta potential tend to be less stable. As shown in Table 2, both of the blank GNP and SP-GNP possessed stronger negative charge on the surface than blank GNs.
and SP-GNs, indicating the stabilization of phospholipid-coated nanoparticles. Furthermore, SP-GNP showed better encapsulation efficiency and loading capacity than SP-GNs (Table 2).

MTT result

The growth inhibition of 6-OHDA in different concentrations on PC-12 cells was shown in Fig 4A. The cell viability decreased with the increased concentration of 6-OHDA, indicating the role of 6-OHDA in cell apoptosis. Cells treated with 6-OHDA concentration of 100μmol/L showed significantly lower cell viability (p<0.05) than the sham cells.

Fig 4B showed the growth enhancement of SP solution in different concentrations on PC-12 cells. With the concentration of 6-OHDA increasing, the cell viability showed increasing trend when SP concentration was lower than 100nM, but showed a declined trend when SP concentration was up to 1μM or 10μM. From the result, SP can enhance cell growth in low dose while inhibit cell growth in high dose.

Fig 4C revealed the growth enhancement of SP solution and SP-GNP on 6-OHDA treated PC-12 cells. These PC-12 cells treated with SP solution or SP-GNP treatment demonstrated higher cell viability (p<0.05) than those without SP treatment. This illustrated that SP of certain concentration could reduce cell apoptosis caused by 6-OHDA and enhance cell growth. Furthermore, the cell viability with SP-GNP treatment was much higher than those with SP solution treatment (p<0.01). Compared with SP solution, SP-GNP can play a better role to mediate SP entering the cells and execute its role in the inhibition of apoptosis, showing a better therapeutic effect on 6-OHDA treated cells.

Table 2. Characterization of GNs and Lip loaded with or without SP (n = 6).

| Formulation | Particle size (nm) | PDI | Zeta Potential (mV) | Encapsulation Efficiency (%) | Load Capacity (%) |
|-------------|--------------------|-----|---------------------|-------------------------------|------------------|
| Blank GNs   | 107±1.01           | 0.221±0.034 | -20.3±0.8          | -                            | -                |
| Blank GNP   | 166±1.32<sup>*</sup>| 0.145±0.021<sup>*</sup> | -37.6±1.4          | -                            | -                |
| SP-GNs      | 121±1.21           | 0.234±0.041 | -18.2±0.5          | 35.8±1.6                     | 1.34±0.05        |
| SP-GNP      | 172±1.52<sup>*</sup>| 0.107±0.013<sup>*</sup> | -29.6±1.2          | 93.3±1.4<sup>*</sup>         | 5.2±0.02<sup>*</sup> |

Note: PDI, Polydispersity Index.
<sup>*</sup>represents P<0.05 vs blank GNs,
<sup>†</sup>represents p<0.05 vs SP-GNs.

doi:10.1371/journal.pone.0148848.t002
Flow cytometry

**Fig 5** revealed the ratio of apoptosis cells and growth enhancement of SP administrated groups on 6-OHDA treated PC-12 cells. With SP treatment, the ratio of apoptosis in 6-OHDA treated cells decreased, compared with those without SP treatment. Furthermore, the 6-OHDA treated cells with SP-GNP achieved lower ratio of apoptosis than those with SP solution treatment. Compared with SP solution, SP-GNP showed better enhancement in SP penetration into the cells, and exhibited stronger inhibition on cell apoptosis.

Behavioral evaluation of PD rats after two-week treatment

The apomorphine-induced rotations following two-week daily treatment of SP in each experimental group were consistent with the DA levels in the diseased brain. As seen in **Table 3**, the order of the reduction in apomorphine-induced rotations was: intranasal SP-GNP > intravenous SP-GNP > intranasal SP solution > intranasal Blank GNP > intranasal PBS ≈ sham.
Fig 5. Flow cytometry results on PC-12 cells. (A) Blank PC-12 cells. (B) 6-OHDA diseased PC-12 cells without treatment. (C) 6-OHDA diseased PC-12 cells with 1nM SP solution treatment. (D) 6-OHDA diseased PC-12 cells with 10nM SP solution treatment. (E) 6-OHDA diseased PC-12 cells with 100nM SP solution treatment. (F) 6-OHDA diseased PC-12 cells with 1nM SP-GNP treatment. (G) 6-OHDA diseased PC-12 cells with 10nM SP-GNP treatment. (H) 6-OHDA diseased PC-12 cells with 100nM SP-GNP treatment.

doi:10.1371/journal.pone.0148848.g005

Table 3. Apomorphine-induced rotations after two-week daily SP treatment (n = 6/group).

| Group | Rats             | Administration | Rotations (r/min) |
|-------|------------------|----------------|-------------------|
| 1     | Sham             | in.PBS         | 0                 |
| 2     | Hemiparkinsonian | in.PBS         | 7.8±0.6           |
| 3     | Hemiparkinsonian | in.Blank GNP   | 7.4±0.8           |
| 4     | Hemiparkinsonian | in.SP solution | 6.8±1.5           |
| 5     | Hemiparkinsonian | in.SP-GNP      | 6.2±1.3*          |
| 6     | Hemiparkinsonian | in.SP-GNP      | 4.7±1.9**         |

Note: in. represents intranasal administration; iv. represents intravenous administration.
* represents p<0.05 vs hemiparkinsonian group;
** represents p<0.01 vs hemiparkinsonian group.

doi:10.1371/journal.pone.0148848.t003
group. The hemiparkinsonian rats received intranasal blank GNP treatment showed little difference from those with intranasal PBS treatment. However, the rotations of the hemiparkinsonian rats with SP administration were lower than those without SP administration, demonstrating that SP could enhance the recovery of diseased dopaminergic neurons in hemiparkinsonian rats. In the meantime, hemiparkinsonian rats treated with intranasal SP-GNP (p = 0.001) and intravenous SP-GNP (p = 0.02) showed a significant decrease on apomorphine-induced rotation than hemiparkinsonian rats with intranasal PBS solution treatment, while those with intranasal SP solution and blank GNP treatment showed a trend of improvement without statistical significance (p = 0.15 and p = 0.35 respectively). From the result, SP-GNP could play a better role on the recovery of diseased dopaminergic neurons in hemiparkinsonian rats than intravenous SP-GNP and intranasal SP solution.

Histopathological observation

The HE staining of the right substantia nigra in each group of rats was shown in Fig 6. Compared with normal group (Fig 6A), hemiparkinsonian model group and the group receiving blank GNP group (Fig 6B and 6C) showed apparently reduced cell numbers, with large number of glial cell proliferation, inflammatory cell infiltration and connective tissue proliferation observed. After SP treatment, there was an obvious increase of neuron number and a reduction in glial cell proliferation, inflammatory cell infiltration and connective tissue hyperplasia. Compared with the rats with SP solution treatment and intravenous SP-GNP

Fig 6. Histopathological HE staining. (a) Sham SD rats. (b) Hemiparkinsonian rats with intranasal PBS treatment. (c) Hemiparkinsonian rats with intranasal blank GNP treatment. (d) Hemiparkinsonian rats with intranasal SP solution treatment. (e) Hemiparkinsonian rats with intravenous SP-GNP treatment. (f) Hemiparkinsonian rats with intranasal SP-GNP treatment.

doi:10.1371/journal.pone.0148848.g006
treatment (Fig 6D and 6E), rats with intranasal SP-GNP treatment (Fig 6F) possessed a larger number of neurons with regular arrangement. The glial cell proliferation, inflammatory cell infiltration and connective tissue proliferation were obviously limited in intranasal SP-GNP group, following with intravenous SP-GNP and intranasal SP solution groups. Result from the histopathological observation further supported the data of behavioral evaluation mentioned in Table 3.

Immunohistochemical staining of TH, p-c-Jun and Caspase-3 levels in diseased SN region

TH immunohistochemical staining was shown in Fig 7A. Image-Pro Plus 6.0 was used to quantify the cells, the staining area and the staining degrees. TH immunohistochemistry in diseased SN region revealed severe loss of dopaminergic cells in hemiparkinsonian group and in the blank GNP treated group, compared with sham group. More TH-positive staining was seen in SP administration groups (p<0.05) than in hemiparkinsonian group, illustrating the enhancement of SP on the recovery of diseased dopaminergic neurons. Among SP administered groups, intranasal SP-GNP group (p<0.01) showed more TH-positive staining than intranasal SP solution group and intravenous SP-GNP group. From the result, intranasal SP-GNP can effectively mediate SP into the brain through the nose and exhibit its neuro-recovery function in the damaged areas of the brain.

Fig 7. Immunohistochemical staining. (a) Sham SD rats with intranasal PBS treatment. (b) PD rats with intranasal PBS treatment. (c) PD rats with intranasal blank GNP treatment. (d) PD rats with intranasal SP solution treatment. (e) PD rats with intravenous SP-GNP treatment. (f) PD rats with intranasal SP-GNP treatment. * represents p<0.05 vs hemiparkinsonian group (Group b), ** represents p<0.01.

doi:10.1371/journal.pone.0148848.g007
From p-c-Jun immunohistochemistry in diseased SN region (Fig 7B), sham-PBS/IN group showed little staining, while hemiparkinsonian group and the blank GNP group showed extremely high levels of staining. It indicated that p-c-Jun was rarely expressed in normal circumstances but expressed in large amount when PD occurred. Less staining was seen in SP administration groups than hemiparkinsonian group (p<0.05), indicating that SP might block the JNK pathway activation, inhibit the expression of p-c-Jun, and thus slow down the PD disease process. Among SP administration groups, intranasal SP-GNP group showed less staining than intranasal SP solution group and intravenous SP-GNP group (p<0.01), demonstrating the effective inhibition of intranasal SP-GNP on the JNK pathway and the p-c-Jun expression in the brain.

As shown in Fig 7C, Caspase-3 immunohistochemistry in diseased SN region revealed little staining in sham-PBS/IN group and extremely high levels of staining in hemiparkinsonian group and the blank GNP group. From the result, Caspase-3 was rarely expressed in normal circumstances but expressed in large amount when PD occurred. Less staining was observed in SP administration groups than in hemiparkinsonian group (p<0.05). Therefore, SP could reduce neuron apoptosis, inhibit the expression Caspase-3, and promote the recovery of the diseased neurons. Among SP administration groups, intranasal SP-GNP group showed less staining than intranasal SP solution group and intravenous SP-GNP group, further supporting the efficiency SP-GNP for SP delivery into the diseased SN region.

Western Blot assessment of TH, p-c-Jun and Caspase-3 levels in diseased SN region

Western Blot was conducted to analyze the TH, p-c-Jun and Caspase-3 levels in diseased SN region quantitatively. As shown in Fig 8, TH levels in hemiparkinsonian group and the blank GNP group were much less than those in the sham group. Compared with hemiparkinsonian group, SP treatment groups showed increased TH levels (p<0.05), proving the SP therapeutic...
action for diseased dopaminergic neurons. Among SP administration groups, intranasal SP-GNP group showed higher TH level than the intranasal SP solution group and intravenous SP-GNP group, suggesting the effective neuro-recovery function of intranasal SP-GNP in the brain.

As for the p-c-Jun and Caspase-3 levels in diseased SN region, the sham group showed both very low concentration of p-c-Jun and Caspase-3 while hemiparkinsonian group and the blank GNP group revealed quite high level of them. From the result, p-c-Jun and Caspase-3 were rarely expressed in normal circumstances but expressed in large amount when PD developed. Compared with hemiparkinsonian group, SP treated groups showed decreased levels in p-c-Jun and Caspase-3 (p < 0.05). It suggested that SP could play a role in reducing neuron apoptosis and inhibiting the expression of p-c-Jun and Caspase-3. Among SP treated groups, the p-c-Jun and Caspase-3 levels in intranasal SP-GNP group were much lower than intranasal SP solution group and intravenous SP-GNP group, demonstrating the enhancement of the intranasal SP-GNP for SP penetration into the brain. In the meantime, the relative destiny of p-c-Jun level was lower than that of Caspase-3 level in hemiparkinsonian group and other groups with treatment. All the results from Western Blot and immunohistochemical staining were consistent with the results of histopathological observation and behavioral evaluation of PD rats.

Discussion

Current therapies for Parkinson’s disease have limitations due to the presence of BBB which prevents therapeutic chemicals or biologics entering the brain. As a member of the tachykinin peptide family, SP can play an important role in treating diseased dopaminergic neuron through deactivation of JNK pathway and inhibition of neuron apoptosis. But SP is a macromolecule which can not penetrate the BBB. In this study, a novel gelatin nanoparticle encapsulating SP was prepared to investigate the role of SP in enhancing neuro-recovery on hemiparkinsonian rats via the noninvasive intranasal route.

Gelatin nanoparticle mediated intranasal delivery of therapeutics to CNS

Therapeutic biologic particles with a size below 300 nm can bypass BBB and gain access to the brain directly through the cribriform plate, and then execute their therapeutic effects [26]. They are believed to gain access to the CNS after intranasal administration via the following pathways: the systemic circulation in which the drug has to cross the BBB; the olfactory pathway in which the drug is taken up by the olfactory epithelium and enter the olfactory bulb; and the trigeminal pathway in which the drug is transported via the trigeminal nerve system [41, 42]. However, their residence time at the delivery site is quite limited due to the mucociliary clearance mechanisms, which restricts their concentration level in CNS and their biological activity as well.

Researchers have demonstrated that lipid nanoparticles mediated intranasal delivery of therapeutics can gain access directly into the brain and achieve effective treatment on brain diseases such as cerebral ischemic [43] and Parkinson’s disease [44]. It has been reported that nonionic surfactants, like Poloxamer 188, might increase transcellular transport of olanzapine by reduction of the barrier function of the mucous layer due to their ability to reduce the mucous viscosity and elasticity, or to modulate the tight junction [45]. In recent years, gelatin is adopted for nanoparticle preparation due to its biocompatibility, biodegradability, low immunogenicity and surface modification. Studies have shown that modified gelatin mixed with Poloxamer 188 can generate nanoparticles that may be used for intranasal drug delivery [46]. Intranasal administrated gelatin nanoparticle, which is prepared with Poloxamer 188 and
gelatin, can bypass BBB and find their way right into CNS through the olfactory pathway and the trigeminal pathway, and then the loaded drugs can play therapeutic role in CNS. In the meantime, gelatin nanoparticle possesses stronger negative charge, which can reduce mucociliary clearance, extend the resident time at the delivery site and enhance the therapeutic effect when intranasally administrated [33–35].

The role of SP in treating diseased dopaminergic neuron through deactivation of JNK pathway and inhibition of neuron apoptosis

From previous studies, SP administrated intracerebroventricularly in a suitable concentration can inhibit both of the activation of JNK pathway and the expression of caspase-3 [1, 16], showing significant functional improvement of Parkinson’s disease [9–11]. However, its therapeutic effect in vivo is limited due to the poor permeability into BBB when administered intravenously.

PC—12 cell, a monoamine cell derived from pheochromocytoma of the male rat adrenal medulla which expresses Tyrosine hydroxylase (TH) and synthesise dopamine inside of cell, is widely used to study Parkinson’s disease model in vitro [47]. In this study, PC-12 cells were used to examine the growth enhancement of SP in vitro. From the result, SP within a certain range of concentrations can enhance cell growth and decrease apoptosis, supporting the therapeutic application for Parkinson’s disease.

For in vivo experiment, 6-OHDA was injected into the right-side striatum of rats to create hemiparkinsonian rat model. Those rats were then divided into 6 groups and administrated SP solution or SP-loaded gelatin nanoparticle intranasally or intravenously. Finally, the rats were sacrificed and the levels of TH, p-c-Jun and caspase-3 were evaluated through immunohistochemical study and Western Blot analysis. From this study, SP can play an important role in deactivation of JNK pathway and inhibition of expression of capase-3, thus recovering the diseased dopaminergic neurons and decreasing the neuron apoptosis in hemiparkinsonian rats.

Though the levels of p-c-Jun and caspase-3 decrease when hemiparkinsonian rats are administrated with SP, it is still unknown whether the reduction of caspase-3 level is mainly caused by deactivation of JNK pathway or by the inhibition of expression of capase-3. Researchers showed that JNK signaling pathway downstream mitochondrial malfunction can lead to over-expression of Caspase-3 protein, ultimately leading to apoptosis or degenerative death of cells [13]. SP can regulate p38 MAPK pathway, JNK pathway, and activate ERK pathway, thereby regulating the expression of caspase family of proteins and cell apoptosis, and improving the symptoms of various brain diseases [15, 16]. It remains unclear whether deactivation of JNK pathway or inhibition of expression of capase-3 is the dominating factor in the role for decreasing the neuron apoptosis.

Therapeutic effect of SP-GNP on 6-OHDA induced PC-12 cell and hemiparkinsonian rats

In this study, novel SP-GNP was prepared and administrated to 6-OHDA induced PC-12 cells and hemiparkinsonian rats via the noninvasive intranasal route. Then the therapeutic effects of SP-GNP and pure SP solution on 6-OHDA induced hemiparkinsonian rats were assessed by quantifying rotational behavior and the levels of tyrosine hydroxylase (TH), phosphorylated c-Jun protein (p-c-Jun) and Caspase-3 (Cas-3) expressed in substantia nigra (SN) region.

From the in vitro experiment, PC-12 cells under SP-GNP treatment showed better cell viability (Fig 4C) and lower degree of apoptosis (Fig 5) than those under SP solution treatment. Hemiparkinsonian rats under intranasal SP-GNP administration demonstrated better behavioral improvement (Table 3), neuron regeneration (Fig 6), higher TH levels in SN (Fig 7) along
with much lower extent of p-c-Jun and Cas-3 (Fig 8) than those under intranasal SP solution administration. Compared with SP solution, SP-GNP showed more effective penetration for PC-12 cells and BBB, along with the stronger inhibition of cell apoptosis both in vitro and in vivo. Histopathological study also illustrated the good biocompatibility of SP-GNP with 6-OHDA treated neuron.

Conclusions

To sum up, SP can enhance 6-OHDA induced dopaminergic neuron recovery in hemiparkinsonian rats through deactivation of JNK pathway and reduction of dopaminergic neuron apoptosis (S1 Fig). SP-GNP administrated intranasally may be an effective therapy choice for Parkinson’s disease.

Supporting Information

S1 Fig. Shows the mechanism diagram of using gelatin nanoparticle mediated intranasal delivery of neuropeptide substance P to enhance neuro-recovery in hemiparkinsonian rats. (TIF)

Author Contributions

Conceived and designed the experiments: YZZ CZL CTL. Performed the experiments: RRJ WY QL WZY FRT KLM. Analyzed the data: RRJ. Contributed reagents/materials/analysis tools: QX. Wrote the paper: YXW YZZ.

References

1. Shukla AK, Pragya P, Chaouhan HS, Patel DK, Abdin MZ, Kar Chowdhuri D. A mutation in drosophila methuselah resists paraquat induced Parkinson-like phenotypes. Neurobiol Aging. 2014; 35: 2419. e 1–16.
2. Oh M, Kim JS, Kim JY, Shin KH, Park SH, Kim HO, et al. Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy. J Nucl Med. 2012; 53: 399–406. doi: 10.2967/jnumed.111.095224 PMID: 22323779
3. Gagliardi M, Annesi G, Tarantino P, Nicoletti G, Quattrone A. Frequency of the ASP620ASN mutation in VPS35 and Arg1205His mutation in EIF4G1 in familial Parkinson's disease from South Italy. Neurobiol Aging. 2014; 35: 2422. e 1–2.
4. Fiebich BL, Schleicher S, Butcher RD, Craig A, Lieb K. The neuropeptide substance P activates p38 mitogen-activated protein kinase resulting in IL-6 expression independently from NF-kappa B. J Immunol. 2000; 165: 5606–11. PMID: 11067916
5. Betaret R, Greenamyre JT. Regulation of dopamine receptor and neuropeptide expression in the basal ganglia of nonkeys treated with MPTP. Exp Neurol. 2004; 189: 393–403. PMID: 15380489
6. Thornton E, Tran TT, Vink R. A substance P mediated pathway contributes to 6-hydroxydopamine induced cell death. Neurosci Lett. 2010; 481: 64–7. doi: 10.1016/j.neulet.2010.06.057 PMID: 20599990
7. Taquet H, Nomoto N, Rose S, Jenner P, Javoy-Agid F, Mauborgne A, et al. Levels of Met-enkephalin, Leu-enkephalin, Substance P and cholecystokinin in the brain of the common marmoset following long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment. Neuropeptides. 1988; 12: 105–10 PMID: 2468106
8. Barker R. Substance P and neurodegenerative disorders: a speculative review. Neuropeptides. 1991; 20: 73–8. PMID: 1724684
9. Thornton E, Vink R. Treatment with a substance P receptor antagonist is neuroprotective in the intrastriatal 6-hydroxydopamine model of early Parkinson’s disease. PLoS One. 2012; 7: e34138. doi: 10.1371/journal.pone.0034138 PMID: 22485158
10. Krasnova IN, Bychkov ER, Lioudyno VI, Zubareva OE, Dambinova SA. Intracerebroventricular administration of substance P increases dopamine content in the brain of 6-hydroxydopamine-lesioned rats. Neuroscience. 2000; 95:119–7. PMID: 10619467
11. Zhang X, Andren PE, Chergui K, Svenningsson P. Neurokinin B/NK3 receptors exert feedback inhibition on L-DOPA actions in the 6-OHDA lesion rat model of Parkinson’s disease. Neuropharmacology. 2008; 54: 1143–52. doi: 10.1016/j.neuropharm.2008.03.005 PMID: 18423776

12. Pan J, Wang G, Yang HQ, Hong Z, Xiao Q, Ren RJ, et al. K252a prevents nigral dopaminergic cell death induced by 6-hydroxydopamine through inhibition of both mixed—lineage kinase 3/c-Jun NH2-terminal kinase 3(JNK3) and apoptosis—inducing kinase 1/JNK3 signaling pathway. Mol Pharmacol 2007; 72: 1607–18. PMID: 17755652

13. Pan J, Zhang QG, Zhang Y. The neuroprotective effects of K252a through inhibiting MLK3/MKK7/JNK3 signaling pathway on ischemic brain injury in rat hippocampal CA1 region. Neuroscience. 2005; 131: 147–59.

14. Chambers JW, Howard S, LoGrasso PV. Blocking c-Jun N-terminal kinase (JNK) translocation to the nucleus protects against 6-hydroxydopamine-induced cell death in primary nigral cultures and in a rat model of Parkinson’s disease. J Neurosci Res. 2005; 82: 1079–87. doi: 10.1002/jnr.20322 PMID: 15893810

15. Lee E, Park HR, Ji ST, Lee Y, Lee J. Baicalein attenuates astroglial activation in the 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine-induced Parkinson’s disease model by downregulating the expressions of nuclear factor-κB, ERK, and JNK. J Neurosci Res. 2014; 92: 130–39. doi: 10.1002/jnr.23307 PMID: 24166733

16. Giuliani P, Romano S, Ballerini P, Ciccarelli R, Petragnani N, Cicchitti S, et al. Protective activity of guanosine in an in vitro model of Parkinson’s disease. Panminerva Med. 2012; 54: 43–51. PMID: 23241934

17. Barbiero JK, Santiago R, Tonin FS, Boschen S, da Silva LM, Werner MF, et al. PPAR-γ agonist fenofibrate protects against the damaging effects of MPTP in a rat model of Parkinson’s disease. Prog Neuropsychopharmacol Biol Psychiatry. 2014; 53: 35–44. doi: 10.1016/j.pnpbp.2014.02.009 PMID: 24593945

18. Fujita H, Ogino T, Kobuchi H, Fujiwara T, Yano H, Akiyama J, et al. Cell-permeable cAMP analog suppresses 6-hydroxydopamine-induced apoptosis in PC12 cells through the activation of Akt pathway. Brain Res. 2006; 1113: 10–23. PMID: 16945353

19. Li X, Ye X, Li X, Sun X, Lian Q, Tao L, et al. Salidroside protects against MPP+-induced apoptosis in PC12 cells by inhibiting the NO pathway. Brain Res. 2011; 1382: 9–18. doi: 10.1016/j.brainres.2011.01.015 PMID: 21241673

20. Coverñas R, Muñoz R. Cancer progression and substance P. Histol Histopathol. 2014; 29: 881–90. PMID: 24535838

21. Jiang MH, Lim JE, Chi GF, Ahn W, Zhang M, Chung E, et al. Substance P reduces apoptotic cell death possibly by modulating the immune response at the early stage after spinal cord injury. Neuroreport. 2013; 24: 846–51. doi: 10.1097/WNR.0b013e3283650e3d PMID: 23995292

22. Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Delivery Rev. 2012; 64: 614–28.

23. Kabanov AV, Gendelman HE. Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog Polym Sci. 2007; 32: 1054–82. PMID: 20234846

24. Mistry A, Stolnik S, Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm. 2009; 379: 146–57. doi: 10.1016/j.ijpharm.2009.06.019 PMID: 19555750

25. Costantini HR, Illum L, Brandt G, Johnson PH, Quay SC. Intranasal delivery: Physicochemical and therapeutic aspects. Int J Pharm. 2007; 337: 1–23. PMID: 17475423

26. Vyas TK, Shahiwal A, Marathe S, Misra A. Intranasal drug delivery for brain targeting. Curr Drug Deliv. 2005; 2: 165–75. PMID: 16305417

27. Das S, Chaudhury A. Recent Advances in Lipid Nanoparticle Formulations with Solid Matrix for Oral Drug Delivery. AAPS Pharm Sci Tech. 2011; 12:62–76.

28. Wang YX, Xuan S, Port M, Idee JM. Recent advances in superparamagnetic iron oxide nanoparticles for cellular imaging and targeted therapy research. Curr Pharm Des. 2013; 19:6547–58. doi: 10.2174/1381612138016666

29. Upadhyay RK. Drug delivery systems, CNS protection, and the blood brain barrier. Biomed Res Int. 2014; 2014:869269. doi: 10.1155/2014/869269 PMID: 25136634

30. Lee JH, Park G, Hong GH, Choi J, Choi HS. Design considerations for targeted optical contrast agents. Quant Imaging Med Surg. 2012; 2:266–73. doi: 10.3978/j.issn.2223-4322.2012.12.04 PMID: 23289086

31. Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS Pharm Sci Tech. 2011; 12:62–76.

32. Patel S, Chavhan S, Soni H, Babbar AK, Mathur R, Mishra AK, et al. Brain targeting of risperidone-loaded solid lipid nanoparticles by intranasal route. J Drug Target. 2011; 19:468–74. doi: 10.3109/1061186X.2010.523787 PMID: 20958095
33. Sivera M, Kvitek L, Soukupova J, Panacek A, Prucek R, Vecerova R, et al. Silver Nanoparticles Modified by Gelatin with Extraordinary pH Stability and Long-Term Antibacterial Activity. PLoS One. 2014; 9: e103675. doi:10.1371/journal.pone.0103675 PMID: 25098570

34. Elzoghby AO. Gelatin-based nanoparticles as drug and gene delivery systems: reviewing three decades of research. J Control Release. 2013; 172: 1075–91. doi:10.1016/j.jconrel.2013.09.019 PMID: 24096021

35. Lee SJ, Yhee JY, Kim SH, Kwon IC, Kim K. Biocompatible gelatin nanoparticles for tumor-targeted delivery of polymerized siRNA in tumor-bearing mice. J Control Release. 2013; 172: 358–66. doi: 10.1016/j.jconrel.2013.09.002 PMID: 24036198

36. Varshosaz J, Eskandari S, Tabbaghian M. Production and optimization of valproic acid nanostructured lipid carriers by the Taguchi design. Pharm Dev Technol. 2010; 15: 89–96. doi: 10.3109/10837450903013568 PMID: 19952542

37. Varshosaz J, Tabbaghian M, Mohammadi MY. Formulation and optimization of solid lipid nanoparticles of buspirone HCl for enhancement of its oral bioavailability. J Liposome Res. 2010; 20: 286–96. doi: 10.3109/08982100903443065 PMID: 24036198

38. Decressac M, Ulusoy A, Mattsson B, Georgievskva B, Romero-Ramos M, Kirik D, et al. GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson’s disease. Brain. 2011; 134: 2302–11. doi:10.1093/brain/awr149 PMID: 21712347

39. Kemeny S, Dery D, Loboda Y, Rovner M, Lev T, Zuri D, et al. Parkin Promotes Degradation of the Mitochondrial Pro-Apoptotic ARTS Protein. PLoS One. 2012; 7: e38837. doi:10.1371/journal.pone.0038837 PMID: 22792159

40. McLean JR, Smith GA, Rocha EM, Hayes MA, Beagan JA, Hallett PJ, et al. Widespread neuron-specific transgene expression in brain and spinal cord following synapsin promoter-driven AAV9 neonatal intracerebroventricular injection. Neurosci Lett. 2014; 576: 73–8. doi:10.1016/j.neulet.2014.05.044 PMID: 24882721

41. Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci. 2000; 11:1–18. PMID: 10913748

42. Thorne RG, Frey WH 2nd. Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin Pharmacokinet. 2001; 40: 907–46. PMID: 11735609

43. Ahmad N, Umar S, Ashafaq M, Akhtar M, Iqbal Z, Samim M, et al. A comparative study of PNIPAM nanoparticles of curcumin, demethoxycurcumin, and bisdemethoxycurcumin and their effects on oxidative stress markers in experimental stroke. Protoplasma. 2013; 250:1327–38. doi: 10.1007/s00709-013-0516-9 PMID: 23784381

44. Pardeshi CV, Belgamwar VS, Tekade AR, Surana SJ. Novel surface modified polymer-lipid hybrid nanoparticles as intranasal carriers for ropinirole hydrochloride: in vitro, ex vivo and in vivo pharmacodynamic evaluation. J Mater Sci Mater Med. 2013; 24: 2101–15. doi: 10.1007/s10856-013-4965-7 PMID: 23728521

45. Zaki NM, Awad GA, Mortada ND, Abd ElHady SS. Enhanced bioavailability of metoclopramide HCl by intranasal administration of a mucoadhesive in situ gel with modulated rheological and mucociliary transport properties. Eur J Pharm Sci. 2007; 32:296–307. PMID: 17920822

46. Vandelli MA, Rivasi F, Guerra P, Forni F, Arletti R. Gelatin microspheres crosslinked with d,l-glyceraldehyde as a potential drug delivery system: preparation, characterization, in vitro and in vivo studies. Int J Pharm. 2001; 215: 175–84. PMID: 11250103

47. Wu AG, Wong VK, Xu SW, Chan WK, Ng CI, Liu L, et al. Onjisaponin B derived from Radix Polygalae enhances autophagy and accelerates the degradation of mutant α-synuclein and huntingtin in PC-12 cells. Int J Mol Sci. 2013; 14(11): 22618–41. doi: 10.3390/ijms141122618 PMID: 24248062